NICE has approved semaglutide 2.4 mg (Wegovy) for use within specialist weight management services (NICE TA875), subject to specific eligibility criteria including a BMI of 35 kg/m or above (or 32.5 kg/m or above in people from certain ethnic minority backgrounds at higher metabolic risk) alongside at least one weight-related comorbidity
Dizziness may arise from rapid drops in blood pressure (orthostatic hypotension), dehydration due to reduced appetite and food intake, or changes in glucose metabolism if you are also taking diabetes medications
Its the first-ever drug that's a dual GIP and GLP-1 receptor agonist
For example, some studies show that females tend to have slightly more insulin-producing beta cells in their pancreas
Essentially, natural GLP1 helps the body regulate blood sugar levels and control appetite
Although the pathogenetic role of oxidative stress in these diseases is well established, there is still limited evidence on the therapeutic role of GSH in such conditions